Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2012 1
2013 1
2014 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.
Schild SE, Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Geyer SM, Hillman SL, Farr GH Jr, Tazelaar HD, Krook JE, Geoffroy FJ, Salim M, Arusell RM, Mailliard JA, Schaefer PL, Jett JR. Schild SE, et al. Among authors: farr gh jr. Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):943-51. doi: 10.1016/j.ijrobp.2004.01.055. Int J Radiat Oncol Biol Phys. 2004. PMID: 15234027 Clinical Trial.
PURPOSE: This Phase III study was performed to determine whether twice-daily (b.i.d.) radiotherapy (RT) resulted in better survival than once-daily (q.d.) ...
PURPOSE: This Phase III study was performed to determine whether twice-daily (b.i.d.) radiotherapy (RT) resulted in better survival t …
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.
Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A, Goldberg RM. Alberts SR, et al. Among authors: farr gh jr. JAMA. 2012 Apr 4;307(13):1383-93. doi: 10.1001/jama.2012.385. JAMA. 2012. PMID: 22474202 Free PMC article. Clinical Trial.
CONTEXT: Leucovorin, fluorouracil, and oxaliplatin (FOLFOX) is the standard adjuvant therapy for resected stage III colon cancer. Adding cetuximab to FOLFOX benefits patients with metastatic wild-type KRAS but not mutated KRAS colon cancer. ...Increased toxicity and greate …
CONTEXT: Leucovorin, fluorouracil, and oxaliplatin (FOLFOX) is the standard adjuvant therapy for resected stage III colon cancer. Add …
Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.
Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH Jr, Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SR; Alliance for Clinical Trials in Oncology. Huang J, et al. Among authors: farr gh jr. Clin Colorectal Cancer. 2014 Jun;13(2):100-9. doi: 10.1016/j.clcc.2013.12.002. Epub 2013 Dec 28. Clin Colorectal Cancer. 2014. PMID: 24512953 Free PMC article. Clinical Trial.
BACKGROUND: Two arms with FOLFIRI, with or without cetuximab, were initially included in the randomized phase III intergroup clinical trial NCCTG (North Central Cancer Treatment Group) N0147. ...Nevertheless, considering the limitations of this analysis, FOLFOX without the …
BACKGROUND: Two arms with FOLFIRI, with or without cetuximab, were initially included in the randomized phase III intergroup clinical …